Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer ...Middle East

PR Newswire - News
Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer
SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular...

Hence then, the article about biosyngen announces fda fast track designation for bst02 in treatment of liver cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer )

Apple Storegoogle play

Last updated :

Also on site :